Longeveron Inc.
LGVN evidence brief
What we can confirm
- Market Cap:
- $23.4M
What it means
What to watch
Prepared research question
What matters most for LGVN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LGVN
Longeveron Inc. is a clinical-stage biotechnology company developing laromestrocel, an allogeneic stem cell therapy for rare pediatric diseases and aging-related conditions, with a key Phase 2b top-line readout expected in September 2026.
Key risk: Going concern risk
Market Cap
$23.4M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Longeveron Inc. is a clinical-stage biotechnology company developing laromestrocel, an allogeneic stem cell therapy for rare pediatric diseases and aging-related conditions, with a key Phase 2b top-line readout expected in September 2026.
- Lead asset laromestrocel is an allogeneic stem cell therapy derived from bone marrow mesenchymal stem cells from young, healthy adult donors [news · published 2026-08-13].
- Phase 2b ELPIS II trial evaluating laromestrocel for hypoplastic left heart syndrome (HLHS) is on track for September 2026 top-line results [news · published 2026-08-12].
- Cash & equivalents of $10.1M as of 2026-06-30 [sec]; cash runway is expected to fund operations into Q4 2026 [sec_mda · as of 2026-05-13].
- Total revenue of $0.3M and net loss of $6.1M for the period ended 2026-06-30 [sec].
- Selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results [news · published 2026-08-12].
What works
- Laromestrocel has orphan-drug designation for HLHS, a rare pediatric disease with limited treatment options [news · published 2026-08-12].
- The company has secured up to $30M in a private placement, with $15M funded initially, led by institutional investors [news · published 2026-05-13].
- Published clinical trial results indicated laromestrocel increased healthspan, leading to XPRIZE Healthspan recognition [news · published 2026-08-12].
What to weigh
- The company has a going concern risk, with cash runway only into Q4 2026 and a need to raise additional capital [sec_mda · as of 2026-08-12].
- Access to the ATM equity facility is restricted until June 9, 2026, and thereafter only if stock trades above $0.80 per share until September 7, 2026 [sec_mda · as of 2026-05-13].
- Accumulated net losses and minimal revenue ($0.3M) reflect the pre-commercial stage and high R&D spending [sec].
From the filings
Quoted directly from source documents.
Phase 2b ELPIS II top-line results expected September 2026
“On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS)”
News · August 12, 2026
Cash runway extends into Q4 2026
“we expect that our cash and cash equivalents as of March 31, 2026, which include proceeds from the initial closing of the Private Placement, will be adequate to fund operations into the fourth quarter of 2026.”
SEC MD&A · May 13, 2026
Going concern risk due to insufficient cash for one year
“we have prepared a cash flow forecast which indicates that we do not have sufficient cash to meet our minimum expenditure commitments for one year from the date these financial statements are available to be issued and therefore we need to raise additional funds to continue as”
SEC MD&A · August 12, 2026
Laromestrocel is an allogeneic stem cell therapy
“Longeveron (NASDAQ: LGVN) is a clinical stage company that is an emerging force in regenerative medicine, with a particular focus on rare pediatric diseases and aging-related conditions that currently have limited treatment options. The company’s lead asset, laromestrocel, is an allogeneic stem cell therapy derived from healthy”
News · May 14, 2026
Catalyst timeline
- 2026-09-01 · ELPIS II Phase 2b top-line results — Primary efficacy and safety data for laromestrocel in HLHS; will determine next steps for the program.
Risks & what to watch (4)›
Key risks
- Going concern risk — Cash runway only into Q4 2026; company needs additional financing to continue operations beyond that [sec_mda · as of 2026-08-12].
- ATM facility restrictions
- Clinical trial failure risk — ELPIS II Phase 2b results are a binary catalyst; negative data could materially impair the program [news · published 2026-08-12].
- Dilution from capital raises — Future financing likely through equity or convertible debt, diluting existing shareholders [sec_mda · as of 2026-08-12].
What to watch
- Top-line results from ELPIS II Phase 2b trial for HLHS expected September 2026 [news · published 2026-08-12].
- Ability to secure additional financing beyond Q4 2026 cash runway [sec_mda · as of 2026-08-12].
- Progress on XPRIZE Healthspan competition and any related milestones [news · published 2026-08-12].
- Regulatory updates regarding orphan-drug designation and potential commercialization path for laromestrocel [news · published 2026-08-12].
Sources: News · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Longeveron Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Longeveron Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
31
Total value held
$2.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 542,032 | $564K |
| millennium management llc | 446,725 | $465K |
| blackrock, inc. | 224,198 | $233K |
| geode capital management, llc | 203,618 | $212K |
| adar1 capital management, llc | 200,000 | $208K |
| jane street group, llc | 185,656 | $193K |
| beacon pointe advisors, llc | 100,000 | $104K |
| state street corp | 45,380 | $47K |
| vanguard fiduciary trust co | 38,715 | $40K |
| capital investment advisory services, llc | 26,525 | $28K |
Showing top 10 of 31 institutional holders of Longeveron Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 9.7%
- Days to cover
- 3.4
- Shares short
- 2,609,328
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LGVN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Longeveron Inc.?
Longeveron Inc. is a clinical-stage biotechnology company developing laromestrocel, an allogeneic stem cell therapy for rare pediatric diseases and aging-related conditions, with a key Phase 2b top-line readout expected in September 2026.
Who is the CEO of Longeveron Inc.?
Mr. Stephen H. Willard Esq. is the chief executive officer of Longeveron Inc. (LGVN).
Where is Longeveron Inc. headquartered?
Longeveron Inc. (LGVN) is headquartered in Miami, FL, United States.
What therapeutic areas does Longeveron Inc. focus on?
Longeveron Inc. develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.